The main aim of the study is to describe the possible impacts of SARS-CoV-2 and its various genotypes on pregnancy and long-term outcomes among pregnant women and their newborns in Estonia.
All the pregnant women in Estonia who conceived and gave birth between February 27, 2020, and March 1, 2023 were included in the study. Pregnant women will be divided into 2 groups: 1. pregnant women who were diagnosed with COVID-19 during the study period, along with their newborns; 2. control group: pregnant women who did not have COVID-19 during pregnancy, along with their newborns. The following data is collected for each subject: prior vaccination, previous COVID-19 infection, underlying diseases/conditions, hospitalization, need for intensive care, need for mechanical ventilation and/or oxygen therapy, death cases, post-COVID-19 symptoms, pregnancy course and outcomes, possible virus transmission from mother to child, and the newborn's condition or accompanying health issues
Study Type
OBSERVATIONAL
Enrollment
60,739
COVID-19 diagnosis in the health database
University of Tartu
Tartu, Estonia
COVID-19 incidence
Time frame: From enrollment to March 2023
Post-COVID condition incidence
Time frame: From enrollment to March 2023
Chronic diseases incidence
Time frame: From enrollment to March 2023
Newborn condition
Apgar scores at birth
Time frame: From enrollment to March 2023
Mortality
Time frame: From enrollment to March 2023
Hospitalization rate due to COVID-19
Time frame: From enrollment to March 2023
Pregnancy complications incidence
Time frame: From enrollment to March 2023
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.